Zeit | Aktuelle Nachrichten | ||
---|---|---|---|
27.06. | Sanofi's Sarclisa recommended by CHMP for new multiple myeloma indication | ||
27.06. | Pfizer shares positive phase 3 results for haemophilia A and B therapy Hympavzi | ||
27.06. | Winning commercial's AI race with connected CRM and data | ||
26.06. | Gilead Sciences and Kymera enter oncology partnership worth up to $750m | ||
26.06. | MHRA approves Accord Healthcare's Hetronifly to treat aggressive form of lung cancer | ||
26.06. | Ipsen receives CHMP recommendation for Cabometyx in neuroendocrine tumours | ||
26.06. | The Considered appoints Emily Knight-Kristoffersen as chief creative officer | ||
26.06. | More than digital: prioritising the human element in HCP engagement design | ||
25.06. | MHRA becomes founding member of HealthAI Global Regulatory Network | ||
25.06. | J&J's Darzalex recommended by CHMP to treat smouldering multiple myeloma | ||
25.06. | EC approves argenx's subcutaneous Vyvgart for rare autoimmune disease CIPD | ||
25.06. | The value of Medscape Extend - redefining omnichannel engagement with physicians in Europe | ||
24.06. | AstraZeneca/Daiichi Sankyo's Datroway granted FDA accelerated approval for lung cancer | ||
24.06. | Eli Lilly shares promising phase 3 results for once-weekly insulin candidate efsitora alfa | ||
24.06. | Innovation with intention: balancing scientific progress and patient-centricity in oncology | ||
23.06. | PMGroup and Visions4Health launch Excellence in Healthcare Partnerships Awards | ||
23.06. | Sanofi/Regeneron's Dupixent granted FDA approval for bullous pemphigoid | ||
23.06. | First NHS patient treated with CSL Behring's haemophilia B gene therapy Hemgenix | ||
23.06. | Mitigating barriers to recruitment and retention in early stage Alzheimer's trials | ||
20.06. | Boehringer's Spevigo recommended by NICE for generalised pustular psoriasis | ||
20.06. | Ventyx's investigational NLRP3 inhibitor shows promise in Parkinson's disease | ||
20.06. | GCI Health appoints Aneeb Sharif as EMEA head of policy | ||
20.06. | Communicating with HCPs through AI takes finesse, flexibility and the human touch | ||
19.06. | Gilead Sciences' twice-yearly HIV PrEP drug Yeztugo granted FDA approval | ||
19.06. | FDA approves CSL's Andembry to prevent hereditary angioedema attacks |